IL211943A - Method for Determining If Head and Neck Squamous Cell Carcinoma (HNSCC) Is Likely to Benefit from a Drug Targeted to the EGFR Pathway - Google Patents

Method for Determining If Head and Neck Squamous Cell Carcinoma (HNSCC) Is Likely to Benefit from a Drug Targeted to the EGFR Pathway

Info

Publication number
IL211943A
IL211943A IL211943A IL21194311A IL211943A IL 211943 A IL211943 A IL 211943A IL 211943 A IL211943 A IL 211943A IL 21194311 A IL21194311 A IL 21194311A IL 211943 A IL211943 A IL 211943A
Authority
IL
Israel
Prior art keywords
hnscc
patient
benefit
head
cell carcinoma
Prior art date
Application number
IL211943A
Other languages
English (en)
Hebrew (he)
Other versions
IL211943A0 (en
Original Assignee
Biodesix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesix Inc filed Critical Biodesix Inc
Publication of IL211943A0 publication Critical patent/IL211943A0/en
Publication of IL211943A publication Critical patent/IL211943A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Computing Systems (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Software Systems (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Computation (AREA)
  • Data Mining & Analysis (AREA)
  • Artificial Intelligence (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
IL211943A 2009-01-20 2011-03-24 Method for Determining If Head and Neck Squamous Cell Carcinoma (HNSCC) Is Likely to Benefit from a Drug Targeted to the EGFR Pathway IL211943A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/321,393 US7867775B2 (en) 2006-03-31 2009-01-20 Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
PCT/US2009/006269 WO2010085235A1 (en) 2009-01-20 2009-11-20 Selection of head and neck cancer patients for treatment with drugs targeting egfr pathway

Publications (2)

Publication Number Publication Date
IL211943A0 IL211943A0 (en) 2011-06-30
IL211943A true IL211943A (en) 2014-01-30

Family

ID=41559566

Family Applications (1)

Application Number Title Priority Date Filing Date
IL211943A IL211943A (en) 2009-01-20 2011-03-24 Method for Determining If Head and Neck Squamous Cell Carcinoma (HNSCC) Is Likely to Benefit from a Drug Targeted to the EGFR Pathway

Country Status (11)

Country Link
US (1) US7867775B2 (enExample)
EP (1) EP2247954B1 (enExample)
JP (1) JP5025802B2 (enExample)
KR (1) KR101131309B1 (enExample)
AT (1) ATE516503T1 (enExample)
AU (1) AU2009338174B2 (enExample)
CA (1) CA2718113A1 (enExample)
ES (1) ES2368784T3 (enExample)
IL (1) IL211943A (enExample)
TW (1) TWI368737B (enExample)
WO (1) WO2010085235A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7867775B2 (en) * 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway
KR101556726B1 (ko) * 2010-02-24 2015-10-02 바이오디식스, 인크. 질량스펙트럼 분석을 이용한 치료제 투여를 위한 암 환자 선별
US8914238B2 (en) 2011-01-28 2014-12-16 Biodesix, Inc. Method for predicting breast cancer patient response to endocrine therapy
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
US8718996B2 (en) 2012-07-05 2014-05-06 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
CN112710723B (zh) 2015-07-13 2024-11-12 佰欧迪塞克斯公司 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法
WO2017136139A1 (en) 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
WO2018129301A1 (en) 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
EP3665199A4 (en) 2017-08-07 2021-08-11 Genecentric Therapeutics, Inc. METHOD OF SUBTYPING PLATE EPITHELIAL CARCINOMA OF THE HEAD AND NECK
US20210074431A1 (en) * 2017-08-30 2021-03-11 Genecentric Therapeutics, Inc. Gene expression subtype analysis of head and neck squamous cell carcinoma for treatment management
EP3773691A4 (en) 2018-03-29 2022-06-15 Biodesix, Inc. DEVICE AND METHOD FOR IDENTIFICATION OF PRIMARY IMMUNORESISTANCE IN CANCER PATIENTS
WO2022084993A1 (en) * 2020-10-19 2022-04-28 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Rapid and direct identification and determination of urine bacterial susceptibility to antibiotics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60332639D1 (de) 2002-08-06 2010-07-01 Univ Johns Hopkins Verwendung von biomarkern zum nachweis von eierstockkrebs
JP2007506442A (ja) 2003-05-30 2007-03-22 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒ阻害薬への応答に関する遺伝子発現マーカー
US20050267689A1 (en) 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
US20050048547A1 (en) 2003-07-17 2005-03-03 Hongyu Zhao Classification of disease states using mass spectrometry data
WO2005098445A2 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
EP2439284B1 (en) * 2004-03-31 2019-05-08 The General Hospital Corporation Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7867775B2 (en) 2006-03-31 2011-01-11 Biodesix, Inc. Selection of head and neck cancer patients for treatment with drugs targeting EGFR pathway

Also Published As

Publication number Publication date
IL211943A0 (en) 2011-06-30
EP2247954A1 (en) 2010-11-10
JP5025802B2 (ja) 2012-09-12
TW201028688A (en) 2010-08-01
US7867775B2 (en) 2011-01-11
ES2368784T3 (es) 2011-11-22
TWI368737B (en) 2012-07-21
US20090171872A1 (en) 2009-07-02
AU2009338174B2 (en) 2012-02-02
KR101131309B1 (ko) 2012-04-02
KR20110047171A (ko) 2011-05-06
AU2009338174A1 (en) 2010-07-29
ATE516503T1 (de) 2011-07-15
WO2010085235A1 (en) 2010-07-29
EP2247954B1 (en) 2011-07-13
JP2011513728A (ja) 2011-04-28
HK1148073A1 (en) 2011-08-26
CA2718113A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
IL211943A0 (en) Selection of head and neck cncer patients for treatment with targeting pathway
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
JP2011513728A5 (enExample)
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
IL211944A (en) METHOD OF DECISION If a patient with colorectal cancer (CRC) is likely to benefit from a drug inhibitor receptor factor epidermal monoclonal antibody directed to the EGFR pathway
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
CR9390A (es) Mutaciones del receptor del factor de crecimiento epidermico
PH12016501206B1 (en) The use of inhibitors of bruton`s tyrosine kinase (btk)
CY1111676T1 (el) Μεθοδος για την θεραπεια του καρκινου με αντισταση στην γεφιτινιβη
IN2012DN03348A (enExample)
TW200643400A (en) Optical-based sensing devices
PL407779A1 (pl) Sposób ekonomicznego próbkowania i charakteryzowania heterogennych niekonwencjonalnych obszarów węglowodorowych
MX343327B (es) Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa.
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
BR112016008146A2 (pt) Anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos para detectar um câncer, de identificação e de seleção de um paciente com câncer
BR112012026174A2 (pt) anticorpo isolado, ácido nucleico isolado, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, doença ou disfunção, uso do anticorpo, método de tratamento, de determinação e de separação
IN2012DN02145A (enExample)
IN2014DN03447A (enExample)
WO2010031749A9 (en) Compositions and methods for detecting tlr3
GB2523211A (en) MCT protein inhibitor-related prognostic and therapeutic methods
HRP20180130T1 (hr) Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras
BRPI0905656A2 (pt) Anticorpo humanizado a9-integrina anti-humana, polinucleotideo, vetor de expressão, célula hospedeira, método para produzir um anticorpo a9-integrina anti-humana, fármaro terapêutico para artrite reumatóide, método para prevenir ou tratar artrite reumatóide e uso do anticorpo humanizado a9-integrina anti-humana
Murray et al. c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity
WO2012018609A3 (en) Mig6 and therapeutic efficacy

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees